Drug
Triheptanoin
Triheptanoin: highest development phase Phase 3, developed by Ultragenyx Pharmaceutical, United Therapeutics. 10 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Ultragenyx Pharmaceutical, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Triheptanoin NCT05933200 | Phase 3 | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) |
| Triheptanoin NCT02000960 | Phase 2 | Glucose Transporter Type 1 Deficiency Syndrome |
| Triheptanoin NCT07097311 | Phase 2 | Medium-chain Acyl-CoA Dehydrogenase Deficiency |
| triheptanoin NCT02696044 | Phase 2 | Rett Syndrome |
| Triheptanoin NCT02432768 | Phase 2 | Glycogen Storage Disease Type V |
| Triheptanoin NCT02036853 | Phase 2 | Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS) |
| Triheptanoin NCT00947960 | Phase 2 | Adult Polyglucosan Body Disease |
| Triheptanoin NCT03506425 | Phase 1/2 | ALS |
| Triheptanoin NCT03665636 | Phase 1 | Glycogen Storage Disease Type I |
| Triheptanoin NCT06340685 | Phase 1 | Pyruvate Dehydrogenase Complex Deficiency |
Latest
No recent events.
Follow Triheptanoin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.